Gastroparesis Drug Rejection by FDA: Vanda Pharma's Reaction
Thursday, 19 September 2024, 07:45
Gastroparesis Drug Rejection: Vanda's Official Statement
The recent gastroparesis drug rejection by the FDA has led to significant backlash from Vanda Pharmaceuticals. The pharmaceutical company expressed its discontent regarding the non-approval of tradipitant, which was intended for treating delayed gastric emptying.
Implications of the Rejection
- Vanda's frustration highlights patient needs unmet by current options.
- The FDA's evaluation processes are once again scrutinized.
- Potential impact on future drug developments for gastrointestinal disorders.
Response from Vanda Pharmaceuticals
Vanda stated that it would evaluate its options moving forward, emphasizing the need for effective treatments in managing gastroparesis.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.